Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

ARA-290 vs BPC-157 + KPV

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

ARA-290 has stronger documented evidence (Phase 2) than BPC-157 + KPV (Anecdotal + Animal Studies) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. BPC-157 + KPV may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

ARA-290

Phase 2

BPC-157 + KPV

Anecdotal + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

ARA-290 BPC-157 + KPV
Class EPO-derived peptide; innate repair receptor (IRR) agonist Cytoprotective pentadecapeptide (BPC-157) + alpha-MSH-derived tripeptide (KPV) blend
Drug class Tissue Repair Tissue Repair
Mechanism Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect BPC-157 promotes angiogenesis (VEGFR2), stabilises gut barrier function, and accelerates epithelial repair; KPV exerts NF-kB-suppressing anti-inflammatory activity at the colonic mucosa via melanocortin pathway intermediates. Layered: BPC-157 drives repair while KPV damps the inflammatory signal that delays it.
Route SC injection SC / Oral
Half-life ~2 hrs BPC-157 less than 30 min (IV and IM, animal data); KPV ~minutes (rapid clearance)
Dosage (research) 2-4 mg SC daily for 28 days (trial protocol) 250-500 mcg BPC-157 + 500-1000 mcg KPV SC daily near area of concern, or oral compounded form 1-2x daily. Cycle 4-6 weeks on / 2-4 weeks off
Evidence tier Phase 2 Anecdotal + Animal Studies
Research depth 68 indexed (PubMed 51 · CT 4 · EPMC 13) —
Availability Investigational Compounding Restricted
Reported risks Injection site reactions; Phase 2/3 data limited Both components are research compounds with limited human safety data; injection-site reactions; theoretical immune modulation; not FDA-approved for any indication

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick ARA-290 or BPC-157 + KPV?

ARA-290 has stronger documented evidence (Phase 2) than BPC-157 + KPV (Anecdotal + Animal Studies) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. BPC-157 + KPV may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between ARA-290 and BPC-157 + KPV?

ARA-290 is classed as EPO-derived peptide; innate repair receptor (IRR) agonist; BPC-157 + KPV is classed as Cytoprotective pentadecapeptide (BPC-157) + alpha-MSH-derived tripeptide (KPV) blend. Reported mechanism: ARA-290, Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect; BPC-157 + KPV, BPC-157 promotes angiogenesis (VEGFR2), stabilises gut barrier function, and accelerates epithelial repair; KPV exerts NF-kB-suppressing anti-inflammatory activity at the colonic mucosa via melanocortin pathway intermediates. Layered: BPC-157 drives repair while KPV damps the inflammatory signal that delays it. Reported half-life: ARA-290, ~2 hrs; BPC-157 + KPV, BPC-157 less than 30 min (IV and IM, animal data); KPV ~minutes (rapid clearance). Routes in published studies: ARA-290, SC injection; BPC-157 + KPV, SC / Oral.

Which has stronger evidence, ARA-290 or BPC-157 + KPV?

ARA-290 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. ARA-290 is graded Phase 2, with 3 cited sources on its reference page and 68 indexed studies. BPC-157 + KPV is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page.

Which is more accessible, ARA-290 or BPC-157 + KPV?

Neither ARA-290 nor BPC-157 + KPV is an FDA-approved drug. Catalog status: ARA-290, Investigational; BPC-157 + KPV, Compounding Restricted.

Are ARA-290 and BPC-157 + KPV ever combined?

ARA-290 and BPC-157 + KPV appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…